# Ph2 Placebo-Controlled Study for Safety & Ocular Efficacy of SBI-100 Ophthalmic Emulsion in Pts w/ Elevated Eye Pressure

> **NCT06144918** · PHASE2 · COMPLETED · sponsor: **Skye Bioscience, Inc.** · enrollment: 56 (actual)

## Conditions studied

- Primary Open Angle Glaucoma
- Ocular Hypertension

## Interventions

- **DRUG:** SBI-100 Ophthalmic Emulsion, 0.5%
- **DRUG:** SBI-100 Ophthalmic Emulsion, 1.0%
- **DRUG:** SBI-100 Ophthalmic Emulsion, Placebo

## Key facts

- **NCT ID:** NCT06144918
- **Lead sponsor:** Skye Bioscience, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-11-09
- **Primary completion:** 2024-02-22
- **Final completion:** 2024-02-22
- **Target enrollment:** 56 (ACTUAL)
- **Last updated:** 2026-01-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06144918

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06144918, "Ph2 Placebo-Controlled Study for Safety & Ocular Efficacy of SBI-100 Ophthalmic Emulsion in Pts w/ Elevated Eye Pressure". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06144918. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*